Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's has launched its generic Semaglutide Injection in Canada following Health Canada approval received on April 28, 2026. The company is the first to receive a Notice of Compliance (NOC) for generic Semaglutide in Canada, marking the first G7 country to authorize a generic version of this GLP-1 therapy. The product is indicated for once-weekly treatment of type 2 diabetes in adults and is available as a pre-filled pen in 2 mg and 4 mg strengths. The launch builds on Dr. Reddy's earlier introduction of the drug in India under the brand name Obeda® and reflects the company's focus on expanding GLP-1 therapies across global markets.
This is a positive regulatory milestone, being the first generic Semaglutide approval in a G7 country, which could provide meaningful revenue contribution in the medium term given the large and growing GLP-1 market, though no specific revenue guidance or order value was disclosed.